RASolute 302: RMC-6236 vs SOC in PDAC (Pancreatic Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for people with metastatic pancreatic ductal adenocarcinoma (PDAC). We want to see how well the study drug works compared to the standard chemotherapy regimen for PDAC.

What is the Condition Being Studied?

Pancreatic Ductal Adenocarcinoma (PDAC)

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with PDAC, including adenosquamous carcinoma and poorly differentiated carcinoma
Have confirmed metastases (evidence that the cancer has spread)

For more information, please contact the study team at dana.a.warren@duke.edu.

Grupo etario

Adultos

What is Involved?

Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) para:

Get the study drug, which is a pill that you take once per day; OR
Get whatever standard chemotherapy option the study doctor believes will be most beneficial for you

Participation in this study will last for up to 3 years.

Study Details

Full Title

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator?s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Principal Investigator